Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Karyopharm Therapeutics Inc

Overview

Patients with eligible diabetic foot ulcers will be screened, treated, and followed for complete ulcer closure. This is a randomized trial. All patients will receive standard-of-care treatment. Additionally, some patients will receive treatment with topical Selinexor gel and some will receive topical placebo gel.

Approximately 30 patients who meet the eligibility criteria will be enrolled. Eligible patients with diabetic foot ulcers will be screened, randomized, treated, and followed for complete ulcer closure. After screening, qualified patients will be treated for up to 12 weeks. Patients who achieve complete ulcer closure will be followed for an additional 12 weeks. All patients will receive standard-of-care treatment. After randomization some patients will be treated with topical Selinexor gel twice weekly and some patients will be treated with a topical placebo gel twice weekly. Patients receiving Selinexor will be assigned to a sequential treatment cohort, either a 10 μM (μmol/L), 30 μM, or 70 μM dose.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Diabetic Foot Ulcers

Interventions

SelinexorDRUG

Topical gel

Standard-of-CareOTHER

Surgical debridement, sterile saline rinses, and dressing changes.

Vehicle GelOTHER

Topical vehicle gel with no active ingredients.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient has a clinical diagnosis of Type I or Type II diabetes mellitus with an HbA1c ≤ 10.0 and has a BMI ≤40. * The DFU(s) to be treated must be: * Anatomically discrete, * Non-healing, but has persisted for ≤12 months * Measures 1 cm2 ≤ area ≤ 5 cm2 following debridement, * Has a Wagner Grade 1 (i.e., not involving bone, muscle, tendons, or ligaments), * The Target DFU is located distal to the ankle (i.e., below the malleolus), and * Is able to be adequately off-loaded. * The patient has adequate arterial blood supply in the affected limb at screening. * Patient has the inability to perceive 10 grams pressure in the peri-ulcer area and other regions of the affected foot and toes using Semmes-Weinstein 5.07 monofilament at screening. Exclusion Criteria: * Patient has a foot ulcer that is clearly of non-diabetic pathophysiology. * Patient has more than two (2) DFUs on the target lower extremity. * DFU is clinically infected. * Patient has active osteomyelitis of the foot or active, uncontrolled, connective tissue disease

Locations (1)

South Pacific Clinical Trials

Auckland, New Zealand

Outcomes

Primary Outcomes

Presence of Local Skin Reactions (LSR)

Presence of local skin reactions (erythema, edema, pain, tenderness, induration, swelling, wound drainage, purulence, odor, cellulitis, callus, and maceration) within 4 cm of the diabetic foot ulcer wound edge.

Time frame: 84 days

Secondary Outcomes

Ulcer Closure

Proportion of patients in each treatment group with complete ulcer closure of the target diabetic foot ulcer.

Time frame: 84 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.